Literature DB >> 27003878

Magnetic Resonance Imaging of Pituitary Tumors.

Jean-François Bonneville1.   

Abstract

Magnetic Resonance Imaging (MRI) is currently considered a major keystone of the diagnosis of diseases of the hypothalamic-hypophyseal region. However, the relatively small size of the pituitary gland, its location deep at the skull base and the numerous physiological variants present in this area impede the precise assessment of the anatomical structures and, particularly, of the pituitary gland itself. The diagnosis of the often tiny lesions of this region--such as pituitary microadenomas--is then difficult if the MRI technology is not optimized and if potential artifacts and traps are not recognized. Advanced MRI technology can not only depict small lesions with greater reliability, but also help in the differential diagnosis of large tumors. In these, defining the presence or absence of invasion is a particularly important task. This review describes and illustrates the radiological diagnosis of the different tumors of the sellar region, from the common prolactinomas, nonfunctioning adenomas and Rathke's cleft cysts, to the less frequent and more difficult to detect corticotroph pituitary adenomas in Cushing's disease, and other neoplastic and nonneoplastic entities. Finally, some hints are given to facilitate the differential diagnosis of sellar lesions.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 27003878     DOI: 10.1159/000442327

Source DB:  PubMed          Journal:  Front Horm Res        ISSN: 0301-3073            Impact factor:   2.606


  8 in total

Review 1.  Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas.

Authors:  Georgia Ntali; John A Wass
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

2.  Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.

Authors:  Sema Ciftci Dogansen; Gulsah Yenidunya Yalin; Seher Tanrikulu; Sakin Tekin; Nihan Nizam; Bilge Bilgic; Serra Sencer; Sema Yarman
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

3.  Densely granulated adenoma pattern is associated with an increased risk of obstructive sleep apnea in patients with acromegaly.

Authors:  Xianchao Zhao; Lijun Heng; Yan Qu; Dong Jia; Jiafeng Ren; Shuyu Sun; Jian Qiu; Jinxiang Cheng; Ting Yang; Junying Zhou; Changjun Su
Journal:  Sleep Breath       Date:  2021-08-12       Impact factor: 2.655

4.  The posterior pharyngeal wall thickness is associated with OSAHS in patients with acromegaly and correlates with IGF-1 levels.

Authors:  Xiaopeng Guo; Yumo Zhao; Man Wang; Lu Gao; Zihao Wang; Zhuhua Zhang; Bing Xing
Journal:  Endocrine       Date:  2018-06-21       Impact factor: 3.633

5.  High levels of IGF-1 predict difficult intubation of patients with acromegaly.

Authors:  Yu Zhang; Xiaopeng Guo; Lijian Pei; Zhuhua Zhang; Gang Tan; Bing Xing
Journal:  Endocrine       Date:  2017-06-15       Impact factor: 3.633

6.  11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy.

Authors:  W A Bashari; M van der Meulen; J MacFarlane; D Gillett; R Senanayake; L Serban; A S Powlson; A M Brooke; D J Scoffings; J Jones; D G O'Donovan; J Tysome; T Santarius; N Donnelly; I Boros; F Aigbirhio; S Jefferies; H K Cheow; I A Mendichovszky; A G Kolias; R Mannion; O Koulouri; M Gurnell
Journal:  Pituitary       Date:  2022-05-24       Impact factor: 3.599

7.  Prediction of high infiltration levels in pituitary adenoma using MRI-based radiomics and machine learning.

Authors:  Chao Zhang; Xueyuan Heng; Wenpeng Neng; Haixin Chen; Aigang Sun; Jinxing Li; Mingguang Wang
Journal:  Chin Neurosurg J       Date:  2022-08-12

8.  Cardiac Abnormalities in Acromegaly Patients: A Cardiac Magnetic Resonance Study.

Authors:  Xiaopeng Guo; Jian Cao; Peijun Liu; Yihan Cao; Xiao Li; Lu Gao; Zihao Wang; Ligang Fang; Zhengyu Jin; Yining Wang; Bing Xing
Journal:  Int J Endocrinol       Date:  2020-02-14       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.